Revolution Medicines (RVMD) Interest Coverage Ratio (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Interest Coverage Ratio of 0.38 for Q1 2026, up 73.0% year-over-year from 0.22 in Q1 2025, and down 101.29% quarter-over-quarter from 29.5 in Q4 2025.
Revolution Medicines (RVMD) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Revolution Medicines' Interest Coverage Ratio history runs 8 years deep, the most recent figure standing at 0.38 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 73.0% year-over-year to 0.38; the TTM figure through Mar 2026 stood at 1.19 (up 74.35% YoY), while the FY2025 annual figure was 1.34, up 46.49% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 0.38, down from 29.5 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 77.01 in Q4 2024, with the low at 1.41 in Q1 2025.
- The 5-year median for Interest Coverage Ratio is 0.84 (2022), against an average of 8.12.
- The sharpest annual moves came in 2022 and 2024: Interest Coverage Ratio tumbled 208.95% in 2022, then soared 7981.03% in 2024.
- Revolution Medicines' Interest Coverage Ratio stood at 44.08 in 2022, then slumped by 102.22% to 0.98 in 2023, then soared by 7981.03% to 77.01 in 2024, then tumbled by 61.69% to 29.5 in 2025, then slumped by 101.29% to 0.38 in 2026.
- Business Quant data shows RVMD's Interest Coverage Ratio at 0.38 in Q1 2026, 29.5 in Q4 2025, and 0.96 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -55.73 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.19 |
| Mar 31, 2026 | -0.38 |
| Dec 31, 2025 | 29.50 |
| Sep 30, 2025 | -0.96 |
| Jun 30, 2025 | -1.29 |
| Mar 31, 2025 | -1.41 |
| Dec 31, 2024 | 77.01 |
| Sep 30, 2024 | -0.56 |
| Jun 30, 2024 | -0.67 |
| Mar 31, 2024 | -0.91 |
| Dec 31, 2023 | -0.98 |
| Sep 30, 2023 | -1.13 |
| Jun 30, 2023 | -1.02 |
| Mar 31, 2023 | -1.09 |
| Dec 31, 2022 | 44.08 |
| Sep 30, 2022 | -0.84 |
| Jun 30, 2022 | -0.66 |
| Mar 31, 2022 | -0.60 |
| Sep 30, 2021 | -0.55 |
| Jun 30, 2021 | -0.37 |